Johnson & Johnson (JNJ)vsTheravance Biopharma Inc (TBPH)
JNJ
Johnson & Johnson
$254.66
+3.99%
HEALTHCARE · Cap: $613.02B
TBPH
Theravance Biopharma Inc
$17.63
-0.49%
HEALTHCARE · Cap: $908.88M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 87681% more annual revenue ($96.36B vs $109.78M). TBPH leads profitability with a 104.3% profit margin vs 21.8%. TBPH trades at a lower P/E of 7.9x. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
TBPH
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-87.1%
Fair Value
$136.12
Current Price
$254.66
$118.54 premium
Margin of Safety
+67.3%
Fair Value
$59.74
Current Price
$17.63
$42.11 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 39 in profit
Keeps 104 of every $100 in revenue as profit
Conservative balance sheet, low leverage
15.0% revenue growth
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% earnings growth
Smaller company, higher risk/reward
Distress zone — elevated risk
Operating margin of -33.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : TBPH
The strongest argument for TBPH centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 104.3% and operating margin at -33.1%. Revenue growth of 15.0% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : TBPH
The primary concerns for TBPH are EPS Growth, Market Cap, Altman Z-Score.
Key Dynamics to Monitor
JNJ carries more volatility with a beta of 0.26 — expect wider price swings.
TBPH is growing revenue faster at 15.0% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JNJ scores higher overall (57/100 vs 47/100), backed by strong 21.8% margins. TBPH offers better value entry with a 67.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Theravance Biopharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?